Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Carolyn Cheney"'
Autor:
Trupti Joshi, Latha P Ganesan, Carolyn Cheney, Michael C Ostrowski, Natarajan Muthusamy, John C Byrd, Susheela Tridandapani
Publikováno v:
PLoS ONE, Vol 4, Iss 1, p e4208 (2009)
Macrophages are important effectors in the clearance of antibody-coated tumor cells. However, the signaling pathways that regulate macrophage-induced ADCC are poorly defined. To understand the regulation of macrophage-mediated ADCC, we used human B c
Externí odkaz:
https://doaj.org/article/1d810990e74740769cfccbb6b3c42bb3
Autor:
Priscilla Do, Erin Hertlein, Minh Tran, Rosa Lapalombella, Carolyn Cheney, Natarajan Muthusamy, Larry Beaver, Brittany G. Griffin, Yang Liu, Kyle A. Beckwith, Xiaokui Mo, John C. Byrd
Publikováno v:
J Immunol
The clinical benefit of CTLA-4 blockade on T cells is known, yet the impact of its expression on cancer cells remains unaddressed. We define an immunosuppressive role for tumor-expressed CTLA-4 using chronic lymphocytic leukemia (CLL) as a disease mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f4ccd938dcdd5c071339ca3d4cf8e3b
https://doi.org/10.4049/jimmunol.1801359
https://doi.org/10.4049/jimmunol.1801359
Autor:
Priscilla Do, Swagata Goswami, Ulf Grawunder, Rajeswaran Mani, Ann Marie Ventura, Sara Elgamal, Frank Frissora, Erich Williams, Carolyn Cheney, Chi-Ling Chiang, John C. Byrd, Natarajan Muthusamy, Christoph Rader, Haiyong Peng, Xiaokui Mo, Jessica Nunes, Lorenz Waldmeier, Roger R. Beerli, Eileen Y. Hu, Meixiao Long, Kevan Zapolnik
Publikováno v:
Blood Adv
Antibody-drug conjugates directed against tumor-specific targets have allowed targeted delivery of highly potent chemotherapy to malignant cells while sparing normal cells. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f7f002768f599ca3032959173f5332
https://pubmed.ncbi.nlm.nih.gov/34424320
https://pubmed.ncbi.nlm.nih.gov/34424320
Autor:
William Blum, Sumithira Vasu, Xiaokui Mo, Rajeswaran Mani, Katherine Walsh, Natarajan Muthusamy, Bhavana Bhatnagar, Donna Bucci, Karl-Heinz Heider, Irene Waizenegger, Alison Walker, Bhavani Gopalakrishnan, Carolyn Cheney, Rebecca B. Klisovic, Bjoern Rueter
Publikováno v:
Oncotarget
Acute myeloid leukemia (AML) is the second most common type of leukemia in adults. Incidence of AML increases with age with a peak incidence at 67 years. Patients older than 60 years have an unfavorable prognosis due to resistance to conventional che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d40bf3c44e97dc686ac8cf8013dd2343
https://doi.org/10.18632/oncotarget.23880
https://doi.org/10.18632/oncotarget.23880
Autor:
Catherine A. Fabian, Rose Mantel, Lisa Smith, Amy Lehman, Sean D. Reiff, John C. Byrd, Elizabeth M. Muhowski, Carolyn Cheney, Jennifer A. Woyach, Wendy B. Young, Lichuan Liu, Adam R. Johnson, Amy J. Johnson, Daphne Guinn
The clinical success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as an effective strategy for treating hematologic malignancies, including chronic lymphocytic leukemia (CLL). Despite ibrutinib’s ability to produce durable remissi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dccaa6562a591165be606c02210c50b5
https://europepmc.org/articles/PMC6128087/
https://europepmc.org/articles/PMC6128087/
Autor:
Xiaokui Mo, Natarajan Muthusamy, Jonathan P. Butchar, William E. Carson, Kerry A. Rogers, Tim Hung-Po Chen, Christopher R. Lucas, Susheela Tridandapani, Carlos E. Castro, Emily M. McWilliams, John C. Byrd, Bonnie K. Harrington, Amanda Campbell, Leslie A. Andritsos, Ronni Wasmuth, Carolyn Cheney, Farrukh T. Awan, Erin Hertlein, Jennifer A. Woyach
Publikováno v:
Blood advances. 3(3)
The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib has transformed chronic lymphocytic leukemia (CLL) therapy but requires continuous administration. These factors have spurred interest in combination treatments. Unlike with chemotherapy, CD20-dir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd209ab6ac544001c28dcb9c4175372a
https://pubmed.ncbi.nlm.nih.gov/30737226
https://pubmed.ncbi.nlm.nih.gov/30737226
Autor:
John P. Vasilakos, Kavin Fatehchand, Huiqing Fang, Shalini Gautam, Jonathan P. Butchar, Saranya Elavazhagan, Brenda F. Reader, Xiaokui Mo, Robert M. Hershberg, Gregory N. Dietsch, Vikram Santhanam, John C. Byrd, Michael A. Caligiuri, Carolyn Cheney, Li Ren, Susheela Tridandapani, Edward L. Briercheck
Publikováno v:
The Journal of Immunology. 194:2786-2795
Fcγ receptors (FcγR) are critical mediators of monoclonal antibody cancer therapies, as they drive cytotoxic processes upon binding of effector cells to opsonized targets. Along with natural killer (NK) cells, monocytes are also known to destroy an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3de48716decfa5f88ab56aa6be0132c5
https://doi.org/10.4049/jimmunol.1402316
https://doi.org/10.4049/jimmunol.1402316
Autor:
Joseph M. Flynn, John C. Byrd, Kami J. Maddocks, Jennifer A. Woyach, Amy Lehman, Kyle A. Beckwith, Carl H. June, Natarajan Muthusamy, Joseph A. Fraietta, Leslie A. Andritsos, Amber Gordon, Bethany L. Mundy, Jeffrey A. Jones, Carolyn Cheney, Farrukh T. Awan, Marcela V. Maus, Priscilla Do, Amy J. Johnson, Michael A. Caligiuri, Meixiao Long
BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f34b58ee36a683b5530dfb645e98da05
https://europepmc.org/articles/PMC5531425/
https://europepmc.org/articles/PMC5531425/
Autor:
Kay Huebner, Thomas J. Rosol, Sean W. Harshman, Chengsi Huang, Charles L. Shapiro, Michael A. Freitas, Michael E. Hoover, Vicki H. Wysocki, Owen E. Branson, Carolyn Cheney, Sarah B. Chaney
Publikováno v:
Journal of Proteome Research
Breast cancer is the second leading cause of cancer-related deaths in women. The need for new clinical biomarkers in breast cancer is necessary to further predict prognosis and therapeutic response. In this article, the LC-MS histone H1 phosphorylati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::598ab4b6f6bf50659a29588a603412af
https://doi.org/10.1021/pr401248f
https://doi.org/10.1021/pr401248f
Autor:
Xiaoli Zhang, Joseph J. Buggy, Natarajan Muthusamy, Ronald Levy, Sarwish Rafiq, Holbrook E Kohrt, Carolyn Cheney, Sarah E. M. Herman, Idit Sagiv-Barfi, Jonathon P. Butchar, Amy J. Johnson, John C. Byrd
Publikováno v:
Blood. 123:1957-1960
To the editor: Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) with promising activity in CD20+ B-cell malignancies including recent US Food and Drug Administration approval in mantle cell lymphoma.[1][1] Given the homology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6541f41dad07dc56282578498ca9f33
https://doi.org/10.1182/blood-2014-01-547869
https://doi.org/10.1182/blood-2014-01-547869